What is pharmaceutical competitive intelligence?
The scope, the deliverables, who consumes them, and the distinction between intelligence and a pile of collected documents.
Reference
Pharmaceutical competitive intelligence, written down properly
Most CI writing is either vendor brochure or academic abstract. This is the working middle: how pipeline tracking, congress coverage and expert interviews actually get combined into something a commercial team can act on.
Where CI teams actually spend their time
Competitive intelligence in pharma is not one discipline. It is four or five overlapping ones, on very different clocks — a regulatory milestone moves on a published date, a congress abstract drops on an embargo, and an investigator's read on a competitor's tolerability data only exists in someone's head until you ask.
Why oncology CI is a different job
Line of therapy, biomarker subsets, combination regimens — why oncology has to be tracked at indication level and what breaks when it isn't.
Congress intelligence: ASCO, ESMO, AACR, ASH
The abstract-to-embargo-to-podium cycle, what late-breakers do to a plan, and why the presented data rarely matches the abstract.
Primary vs secondary intelligence
Secondary tells you what happened. Primary tells you why, and what the people who ran the trial actually think about it.
Pre-launch competitive intelligence
Launch sequencing, anticipated competitor labels and access starting conditions — the market you will actually enter, not the one that exists now.
LOE and biosimilar intelligence
The date is public; the shape of the erosion is not. Why biosimilars behave nothing like generics, and what signals exist under each regime.
CI for business development and licensing
Diligence asks whether differentiation survives to launch, and asks it inside a three-week data-room window.
CI tools and databases
What each category of subscription is genuinely good at, the four questions none of them answer, and how to run an overlap audit.
The recurring failure is not collection
Almost every CI function has more raw material than it can read. ClinicalTrials.gov, earnings transcripts, patent filings, congress abstracts, press releases, regulatory calendars — all of it available, most of it free, none of it scarce.
What is scarce is the judgment to say which three of those four hundred trials change the plan, and the access to ask a trial investigator what the safety signal looked like in the room. That is the part that does not scale by buying another database.